Get Live Data

Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

  2. Share Prices
  3. Physiomics Share Price
  4. Physiomics Share Regulatory News
  5. DoseMeRx Update

Pin to quick picksPhysiomics Regulatory News (PYC)

Physiomics Information

Share Price Information for Physiomics (PYC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.25
Bid: 1.10
Ask: 1.40
Change: 0.00 (0.00%)
Spread: 0.30 (27.273%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.25
PYC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DoseMeRx Update

21 Feb 2022 10:00

RNS Number : 2768C
Physiomics PLC
21 February 2022
 

21 February 2022

Physiomics plc

("Physiomics" or "the Company")

 

DoseMeRx Update

 

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, would like to provide an update on its collaboration with Tabula Rasa Healthcare Inc ("TRHC") in the field of oncology (first announced in December 2020) following THRC's recent press release regarding the intended sale of its DoseMeRx solution.

Physiomics' personalised dosing application for docetaxel in prostate cancer was successfully integrated into the DoseMeRx platform over the course of 2021. Following positive feedback on this proof of concept implementation, Physiomics and DoseMeRx are exploring further development in other cancer indications that may offer more significant commercial potential. During the sale process announced by TRHC, Physiomics continues to work with DoseMeRx and looks forward to further developing the collaboration with DoseMeRx's new owners as and when the transaction is completed.

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0)20 3764 2341

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.

For more information please visit:

 

www.physiomics.co.uk 

www.twitter.com/Physiomics 

www.linkedin.com/company/physiomics-plc/ 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEANAFASLAEEA
123456789
Date   Source Headline
7th Feb 20119:42 amRNSIssue of Options
24th Dec 20109:06 amRNSDirector's Notification
13th Dec 201011:07 amRNSResult of AGM
6th Dec 20107:00 amRNSDirectorate Change
15th Nov 20103:23 pmRNSNew Project and Grant Funding
15th Nov 20107:10 amRNSFinal Results for the year ended 30 June 2010
22nd Sep 20103:10 pmRNSRecent Price Movements
31st Aug 20107:01 amRNSJoint Services Alliance with Jubilant Biosys
14th May 201012:08 pmRNSRecent Price Movements and Press Speculation
16th Mar 20107:00 amRNSCollaboration with Sareum, the ICR and CRT
1st Mar 20107:00 amRNSHalf Yearly Report
8th Feb 20104:22 pmRNSHolding(s) in Company
29th Jan 20102:20 pmRNSTotal Voting Rights
29th Jan 20102:17 pmRNSHolding(s) in Company
22nd Jan 20101:14 pmRNSIssue of Equity
29th Dec 200910:53 amRNSResult of AGM
18th Dec 20091:06 pmRNSConversion of Loan Note
14th Dec 200912:46 pmRNSIssue of Equity
9th Dec 20097:47 amRNSHolding(s) in Company
4th Dec 200911:47 amRNSIssue of Equity
25th Nov 20099:16 amRNSHolding(s) in Company
19th Nov 20099:03 amRNSHolding(s) in Company
16th Nov 20094:50 pmRNSHolding(s) in Company
16th Nov 20097:00 amRNSPhysiomics Presentation
6th Nov 20094:30 pmRNSHolding(s) in Company
5th Nov 20094:22 pmRNSHolding(s) in Company
27th Oct 20094:18 pmRNSHolding(s) in Company
27th Oct 20099:35 amRNSHolding(s) in Company
23rd Oct 20094:23 pmRNSHolding(s) in Company
21st Oct 20099:06 amRNSHolding(s) in Company
20th Oct 20094:01 pmRNSHolding(s) in Company
20th Oct 20093:59 pmRNSHolding(s) in Company
16th Oct 20094:30 pmRNSRecent Price Movements
1st Oct 20093:02 pmRNSTrading Statement
18th Sep 200910:02 amRNSHolding(s) in Company
11th Sep 20093:52 pmRNSHolding(s) in Company
8th Sep 200912:37 pmRNSHolding(s) in Company - Replacement
7th Sep 20094:35 pmRNSHolding(s) in Company
3rd Sep 20099:12 amRNSHolding(s) in Company
28th Aug 20097:56 amRNSTotal Voting Rights
17th Aug 200910:01 amRNSHolding(s) in Company
6th Aug 20094:23 pmRNSConversion of Debt into Equity
24th Jul 20098:01 amRNSHolding(s) in Company
6th Jul 200911:52 amRNSHolding(s) in Company
2nd Jul 20097:53 amRNSHolding(s) in Company
26th Jun 20097:58 amRNSHolding(s) in Company
23rd Jun 20097:00 amRNSUpdate on EC funded TEMPO project
23rd Apr 20094:34 pmRNSHolding(s) in Company
22nd Apr 20094:43 pmRNSHolding(s) in Company
22nd Apr 20094:43 pmRNSHolding(s) in Company
123456789

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.